A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
- Registration Number
- NCT04520646
- Lead Sponsor
- Huashan Hospital
- Brief Summary
Acromegaly is a disease characterized by excess growth hormone(GH) and insulin like growth factor(IGF)-1. Pituitary GH secreting adenoma is the major cause of acromegaly. Acromegalic cardiomyopathy is one of the leading causes of death in acromegalic patients. No efficient medicine is available for acromegalic cardiomyopathy until now and there were limited studies. Empagliflozin is proved to decrease the risk of heart failure in diabetic patients and independent of blood glucose control. We planed to evaluate the structure of heart by MRI before and after 6 months treatment with empagliflozin in acromegalic patients to investigate the effect of empagliflozin on acromegalic cardiomyopathy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 10
- patients with pituitary GH adenomas confirmed by surgery
active acromegalic patients although treated with surgery,radiation therapy and somatostatin analogs
- patients with contraindications to empagliflozin pregnant patients patients with poor control of hypertension(SBP>150mmHg or DBP>95mmHg patients with contraindications to MRI
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description empagliflozin Empagliflozin empagliflozin is added on the basis of the original treatment
- Primary Outcome Measures
Name Time Method Left ventricular mass index 6 months the changes in left ventricular mass index by heart MRI
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Huashan Hospital
🇨🇳Shanghai, Shanghai, China